 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To report a case of possible association of benzalkonium chloride in nebulizer solutions with respiratory arrest and to review the involvement of various preservative agents in paradoxical bronchoconstrictive reactions. DATA SOURCES: Reference articles, case reports, and editorials are identified in the text. DATA SYNTHESIS: Many pharmacologic agents are available for nebulization. In addition to the active drug, these nebulizer solutions may contain preservatives. We describe a case of respiratory arrest in a 64-year-old man following nebulization therapy with albuterol and ipratropium solutions. These solutions contain benzalkonium chloride as a preservative. We are aware of only one report describing two deaths associated with such a severe reaction attributable to nebulization therapy. However, many reports of milder paradoxical bronchoconstriction are available in the medical literature. CONCLUSIONS: Clinicians should be aware of the possibility of paradoxical bronchoconstrictive reactions when patients are treated with nebulized bronchodilators.
This article has been cited by other articles:
|
|
 |
|
  K. Blake, R. Madabushi, H. Derendorf, and J. Lima Population Pharmacodynamic Model of Bronchodilator Response to Inhaled Albuterol in Children and Adults With Asthma Chest, November 1, 2008; 134(5): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reznik, I. Sharif, and P. O. Ozuah Inner-City Availability of Preservative-Containing Albuterol Clinical Pediatrics, September 1, 2004; 43(7): 615 - 617. [Abstract] [PDF]
|
|
|
|
 |
|
 Committee on Drugs "Inactive" Ingredients in Pharmaceutical Products: Update (Subject Review) Pediatrics, February 1, 1997; 99(2): 268 - 278. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
